Akari Therapeutics Plc

Snapshot

Akari Therapeutics is a clinical-stage biotech with no revenue and a strained balance sheet. The company burned $17.3 million in net income during FY 2025 and holds only $5.2 million in cash. At its current burn rate, that cash lasts approximately 1.5 months. The company recently raised $5.5 million through a private placement, which extends the runway but comes with significant dilution.

What's Happening Right Now

• Thu 21st May '26 · Financing: Akari priced a $5.5 million private placement to fund its lead cancer drug candidate, AKTX-101, toward a Phase 1 trial.
• Thu 21st May '26 · Preclinical Data: Akari reported positive preclinical data showing its lead drug works synergistically with existing KRAS inhibitors in pancreatic cancer models.
• Mon 18th May '26 · Filing Delay: The company delayed its quarterly report and warned of a material non-cash impairment charge due to its collapsing market value.
• Mon 6th Apr '26 · Partnership: Akari announced a strategic partnership with WuXi XDC to accelerate the development of its novel antibody-drug conjugate payload.
• Tue 17th Mar '26 · Reverse Split: The company executed a 1-for-40 reverse stock split in March 2026, a move typically taken by stocks under severe price pressure.